Clinical Trial Update: Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dasatinib with everolimus in pediatric and young adult gliomas with PDGFR alterations was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma
• High-grade Glioma

Drugs mentioned

• DASATINIB (Dasatinib)
• Everolimus (everolimus)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Glioma, High Grade Glioma | Phase 2 | Status: TERMINATED | Results posted: 2022-10-05